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Angiogenesishasbeenwellrecognizedasafundamentalpartofamultistepprocessintheevolutionofcancerprogression,invasion,
and metastasis. Strategies for inhibiting angiogenesis have been one of the most robust ﬁelds of cancer investigation, focusing on
the vascular endothelial growth factor (VEGF) family and its receptors. There are numerous regulatory drug approvals to date
for the use of these agents in treating a variety of solid tumors. While therapeutic eﬃcacy has been established, challenges remain
with regards to overcoming resistance and assessing response to antiangiogenic therapies. Prostate cancer is the most common
noncutaneous malignancy among American men and angiogenesis plays a role in disease progression. The use of antiangiogenesis
agents in prostate cancer has been promising and is hereby explored.
1.Introduction
Angiogenesis is a complex, dynamic process that involves
multiple pathways that converge to aﬀect carcinogenesis,
proliferation, and tumor growth. Since the inception of the
concept of angiogenesis by Dr. Judah Folkman decades ago,
a substantial body of research has emerged and currently
forms the groundwork for establishing antiangiogenesis as
an important part of the armamentarium in cancer therapy.
Furthermore, investigation of signaling pathways, molecules,
drugs, as well as mechanisms of resistance may lead to
a better understanding of angiogenesis and the develop-
ment of strategies incorporating antiangiogenic drugs with
chemotherapy in various tumor types, such as prostate
cancer.
Prostate cancer is the leading noncutaneous malignancy
among American men in North America. In 2009 alone, it
is estimated that 192,280 new cases will be diagnosed and
more than 27,000 deaths will occur from this disease [1].
Hormonal therapy remains the cornerstone of treatment
for men who have androgen-responsive metastatic disease.
While most men will respond to sequential hormonal
manipulations, castration resistant prostate cancer (CRPC)
eventually ensues. The demonstration of survival beneﬁt
using docetaxel-based therapy [2, 3] led to the approval
by the Food and Drug Administration (FDA) in 2004 of
docetaxel and prednisone for the treatment of metastatic
CRPC. Since then, no other drug has been approved for
metastatic CRPC, thus creating an area of increased unmet
medical need.
Extensive studies on angiogenesis in prostate cancer to
date have revealed that angiogenesis plays a role in the prog-
ression of prostate cancer. Microvessel density, a measure-
ment of prostate cancer angiogenesis, has been shown to
be a predictor of metastasis and survival [4]. Thus, targeting
angiogenesis has been the subject of several clinical investi-
gations.
2.PathwaysInvolvedinthe AngiogenicProcess
Since the introduction of the concept that tumors would not
grow beyond a pinhead size in the absence of blood vessel2 Journal of Oncology
growth [5], our understanding of the role that angiogenesis
plays in cancer has robustly expanded. Angiogenesis is a
complex process that involves an interplay between various
regulatory proteins, proangiogenic stimuli, endothelial cell
activation, as well as proliferation and migration, governed
by molecular and cellular mechanisms, resulting in reorgani-
zation into new blood vessels [6]. The theory of the “angio-
genicswitch”describesthedynamictransitiontoamalignant
tumor phenotype that promotes neovascularization, the
absence of which is a rate-limiting step in carcinogenesis
[7–10]. Several factors may trigger proangiogenic factor
expression. Hypoxia, for instance, regulates the production
of several angiogenic cytokines such as ﬁbroblast growth
factor2(FGF-2),vascularendothelialgrowthfactor(VEGF),
transforming growth factor-beta (TGF-β), tumor necrosis
factor-alpha (TNF-α), and interleukin-8 (IL-8), among oth-
ers. The overall tumor microenvironment is also instrumen-
talintherecruitmentofproangiogenicfactors[11],although
the resulting tumor neovasculatures are characterized by
ineﬃcient, permeable, and leaky vessels [12].
Vascular Endothelial Growth Factor Pathway (VEGF). Per-
haps the most widely studied pathway in the angiogenic
signaling process involves triggering VEGF and its receptors.
The VEGF family has more than 7 members, including
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PlGF, and
Trimeresurus ﬂavoviridis (T.f.) svVEGFs [13]. VEGF-A is
the prototype VEGF ligand, playing a key role in tumor
angiogenesis. VEGF-A binds and activates two receptors,
namely, VEGFR1 (Flt-1 or fms-like tyrosine kinase receptor
1) and VEGFR2 (KDR/Flk-1), and it has varying roles in
the promotion of endothelial cell diﬀerentiation, cell growth,
tubular formation, and migration [14]. Neutralization of
the VEGF-A ligand has, therefore, been the subject of
investigation in the last decade, leading to the ﬁrst FDA drug
approval of its class, Bevacizumab (Avastin; Genentech, Inc.,
South San Francisco, CA). Other strategies for targeting the
VEGF pathway involve the inhibition of key enzymes such
as tyrosine kinase inhibitors or use of decoy receptor fusion
proteins.
3. ProstateCancer: Experiencewith Use of
Antiangiogenic Agents
Early studies yielded promising results of VEGF inhibition in
various murine tumor models [15, 16]. In prostate cancer,
elevated circulating VEGF and other soluble growth factors
have been demonstrated to be predictive of biochemical
progression in men undergoing radical prostatectomy [17].
Measurements of angiogenesis using microvessel density
have also been shown to be a prognosticator for survival
and metastasis [4, 18, 19]. The utility of microvessel density
has also been shown to improve prediction of cancer staging
from prostate biopsies, beyond the well-known contributory
factors aﬀorded by existing risk features such as Gleason
scores and prostate-speciﬁc antigen (PSA) levels [20]. In a
prospective study among 572 men diagnosed with prostate
cancer in the Health Professionals Follow-Up Study, those
with the most irregular and primitive microvessel density
as measured by staining CD34 were more likely to have
lethal and aggressive prostate cancer [21]. This section will
discuss varying agents used in the treatment of prostate
cancerincludingthalidomide,bevacizumab,andthetyrosine
kinase inhibitors.
3.1. Thalidomide. Thalidomide (alpha-N-phthalimidogluta-
rimide; Thalomid, Celgene, Summit, NJ) has emerged as a
potent treatment for several disease entities and has been
currently approved by the FDA in the United States, includ-
ing for the treatment of Multiple Myeloma [22]. Although
its antiangiogenic properties are not clearly understood,
several in vitro assays have suggested that the antiangiogenic
properties could be secondary to the inhibition of secretion
of two angiogenic cytokines, namely, VEGF and FGF from
both tumor and stromal cells [23, 24]. Evidence to date
suggests that this occurs independently of thalidomide’s
immunomodulatory properties and that the downregulation
of integrins perhaps results in the inhibition of endothelial
cell migration and adhesion [25]. Although thalidomide
has predominantly been studied in hematologic malignan-
cies, activity in solid tumors has also been demonstrated.
Thalidomide in prostate cancer has been used alone or in
combination with chemotherapy in CRPC. An earlier study
using thalidomide in an open-label phase II randomized
trial compared low-dose (200mg/day) and high-dose (up
to 1200mg/day) thalidomide in 63 patients [26]. Results
showed a modest response with 27% of the patients having a
reduction in the serum PSA levels of ≥40%. Four patients
in the low-dose arm showed sustainable response of >150
days with a >50% decrease in PSA. The demonstration of
the potential activity of thalidomide and preclinical evidence
demonstratingthatchemotherapycouldenhancetheactivity
of antiangiogenic agents [27] led to the combination of
thalidomide with docetaxel [28]. This randomized phase II
study of docetaxel, with or without 200mg of thalidomide,
enrolled 75 patients with chemotherapy-naive metastatic
CRPC. Docetaxel, at a dose of 30mg/m2 given intravenously,
was administered weekly for 3 out of 4 weeks, with a 1-week
rest period during the 4th week. The trial was launched prior
to the TAX 327 trial which demonstrated the superiority
of docetaxel every 3 weeks; thus, the weekly dose was
administered. PSA declines of at least 50% were greater in
the combined docetaxel and thalidomide arm compared to
thedocetaxelalonearm,withbetterprogression-freesurvival
(PFS) which was not statistically signiﬁcant (median PFS
of 3.7 months in docetaxel group and 5.9 months in the
combined group (P = .32)) [29]. The side eﬀects were
manageable although thrombotic events were seen in the
combination arm which was later alleviated by institution of
thromboprophylaxis. Further overall survival analysis of this
trialshowedanimprovementinthe18-monthsurvivalinthe
combination arm versus docetaxel alone arm (69.3% versus
47.2%, P<. 05) [30].
To this end, a search for a more eﬃcacious and less
toxicthalidomideanalogsuchaslenalidomidewasstudiedin
prostate cancer. A phase I study to determine the maximum
tolerated dose (MTD) and to characterize the side-eﬀectJournal of Oncology 3
proﬁle and pharmacokinetics (PKs) of lenalidomide in
patients with advanced refractory solid tumors was launched
[31]. Forty-ﬁve patients were enrolled, of whom 36 patients
had prostate cancer. Dose levels used were 5mg, 10mg,
15mg, 20mg, 25mg, 30mg, 35mg, and 40mg. The dosing
schedule was modiﬁed from continuous daily to 21 out of 28
days of dosing due to the observed side eﬀects. Interestingly,
stable disease was seen in 12 out of 44 evaluable patients, 9
of whom had prostate cancer. A phase I dose-escalation trial
using docetaxel at 60mg/m2 and 75mg/m2 every 21 days,
combined with lenalidomide at varying doses from 10mg
to 30mg on days 1–21, showed promising responses with
manageable toxicity [32]. There were 31 patients evaluable
for PSA response. PSA declines of >50% were seen in 47%
(8 out of 17) previously untreated patients and 50% (7 out
of 14) previously treated patients. The promising activity
seen in prostate cancer, as well as the demonstrated activity
using thalidomide, has led to an ongoing phase II trial using
the combination of lenalidomide, docetaxel, prednisone,
and bevacizumab, in chemotherapy-naive patients with
metastatic CRPC at the National Cancer Institute [33].
3.2. Bevacizumab. Bevacizumab is the most widely stud-
ied antiangiogenic inhibitor and the ﬁrst of its class to
be approved by the United States FDA. It has gained
approval predominantly in combination with chemotherapy
for metastatic colorectal cancer, lung, breast, renal cell
cancer, and Glioblastoma multiforme [34]. Bevacizumab is
a humanized IgG1 monoclonal antibody developed from a
murine monoclonal antibody targeting the human VEGF
ligand, speciﬁcally the major isoforms of VEGF-A. The
initial studies using a murine monoclonal antibody targeting
VEGF on several human cancer cell lines in vivo showed
promising results [15, 35]. However, initial single agent
studies in prostate cancer were disappointing[36]. Fifteen
patients with metastatic CRPC were treated at a dose of
10mg/kg of bevacizumab every 2 weeks for 6 total infusions.
No objective or partial responses were observed by day 70 in
the 8 patients who had measurable disease. Only 4 patients
had PSA declines, none more than 50%. Although single-
agent bevacizumab lacked signiﬁcant activity in prostate
cancer,asinmostothersolidtumors,theencouragingresults
from other clinical trials using combined bevacizumab
and chemotherapy led to a Cancer and Leukemia Group
B (CALGB) trial 90006 that combined bevacizumab with
docetaxel and estramustine [37]. The CALGB 90006 trial
enrolled 79 patients, and a 77% PSA decline rate of 50% was
observed (in the 58 of 75 patients with suﬃcient PSA data)
[37, 38]. The estimated time to progression was 9.7 months
and the overall survival was 21 months.
SimilarpromisingresultswereshowninaphaseII,open-
label trial at the National Cancer Institute (NCI) utilizing
a combination of bevacizumab at 15mg/kg every 3 weeks,
in combination with docetaxel 75mg/m2 every 3 weeks,
thalidomide 200mg daily, and prednisone 10mg daily, with
thromboprophylaxis using a low-molecular weight heparin.
This trial enrolled 60 patients with metastatic CRPC, with
a median age of 66 years (range 44–79), and predominantly
high-riskfeatures,includingamedianGleasonscoreof8,on-
study PSA of 99ng/mL (range: 6.0–4,399), and prestudy PSA
doubling time of 1.6 months (0.3–18.2, 81% <3 months).
As of the last followup [39], 51 patients (88%) had PSA
declines of >50%, with median >50% PSA decline duration
of 11 cycles (0–45). Furthermore, the overall response rate
was 63% of the 32 patients with measurable disease, with a
complete response (CR) seen in 2 patients, partial response
(PR) in 18 patients, and stable disease (SD) in 11 patients.
Thiscombinationwastolerablewithexpectedadverse-eﬀects
that included febrile neutropenia in 5 patients, syncope in 5
patients, gastrointestinal perforation or ﬁstula in 3 patients,
and thrombosis or bleeding in 5 patients. The estimated
median PFS was 18.2 months.
Another CALGB study that evaluated bevacizumab in
prostate cancer was CALGB 90401 which had the primary
objective of comparing overall survival between men with
chemotherapy-naive metastatic CRPC treated with standard
of care docetaxel 75mg/m2 every 21 days and prednisone
5mg twice daily versus docetaxel 75mg/m2, prednisone
5mg twice daily, and bevacizumab 15mg/kg every 21 days.
The study completed accrual in December 2007 and results
are currently awaited. The study was powered to detect a
25% improvement in overall survival in the bevacizumab
arm [40].
3.3. VEGF Trap. Another strategy for targeting VEGF is
through blocking the VEGF receptors. One of the most
potent VEGF-R blockers is a novel decoy receptor fusion
protein comprised of the extracellular domain 2 of VEGFR-
1 and domain 3 of VEGFR-2 fused to the constant region
(Fc fragment) of human IgG1 [41]. Earlier studies using
truncated soluble VEGF-R1 inhibitors exhibited eﬀective
inhibition of VEGF but had poor pharmacokinetic proﬁle
and had to be administered more frequently and at high
concentrations [42, 43]. VEGF Trap (Aﬂibercept; Sanoﬁ
Aventis, Paris, France and Regeneron, Tarrytown, New York)
is a human fusion protein that binds and neutralizes the
major VEGF isoforms including VEGF-A, VEGF-B, as well
as platelet-derived growth factor (PlGF) [44]. A phase I
dose escalation study using aﬂibercept in combination with
docetaxel 75mg/m2 every 3 weeks has been reported [45],
with recommended dosing of aﬂibercept at 6mg/kg. A phase
III trial has been launched in metastatic CRPC patients with
a primary objective of improvement in overall survival for
metastaticCRPCandaplannedaccrualof1,200patientswho
willberandomizedtoeitherVEGFTrapincombinationwith
standarddocetaxelandprednisoneorstandarddocetaxeland
prednisone alone [46].
3.4. Tyrosine Kinase Inhibitors. Tyrosine kinases are key
enzymes that modulate various cellular processes that aﬀect
signaling for tumor growth, proliferation, and survival [47].
Several tyrosine kinase inhibitors have been used in the
treatment of prostate cancer. Sorafenib (Nexavar; Bayer
HealthCare Pharmaceuticals Inc., Wayne, NJ) and sunitinib
(Sutent;Novartis,EastHanover,NJ)leadtheagentsthathave
been used. Sorafenib not only inhibits VEGF but functions
as a multi-tyrosine kinase inhibitor that has been shown4 Journal of Oncology
in preclinical models to inhibit wild-type and mutant b-
Raf and c-Raf kinase isoforms in vitro. In addition, this
agent also inhibits various pathways, including p38, c-kit,
VEGFR-2,andPDGFR-βinvaryingconcentrations,aﬀecting
t u m o rg r o w t ha sw e l la sp o s s i b l yp r o m o t i n ga p o p t o s i sb y
events downstream of c-Raf [48, 49]. Clinical studies using
sorafenib have been done in various phase II studies but have
shown only modest activity and no robust PSA declines. In a
phase II study using sorafenib in 22 patients, no PSAdeclines
of 50% were noted [50]. However, there was discordance
between PSA rise and improvement in bone lesions by bone
scintigraphy scan in two patients. This led to further accrual
of the trial to the accrual goal of 46 patients [51]. Other
phase II studies using sorafenib showed similar minimal PSA
activity in spite of radiographic improvements [52–56].
Sunitinib malate is another small molecule inhibitor
targeting VEGFR-1 and VEGFR-2, along with PDGF-R, c-
kit, and RET kinases [57]. This agent has been shown to
exhibit some activity in prostate cancer. However, similar to
sorafenib, sunitinib exhibited few PSA declines and several
patients had clinical and radiographic improvements despite
PSA rises [58]. The use of these agents, therefore, raises the
question of whether adequate assessments are being used
in analyzing the treatment eﬀects using these multikinase
inhibitors or perhaps they are best combined with other
agents, such as chemotherapy.
Cediranib (Recentin; AstraZeneca, London, UK) is
another agent that inhibits tyrosine kinases of VEGF recep-
tors. This is an oral, potent, indole-ether quinazoline ATP-
competitive compound that inhibits proliferation via inhibi-
tion of all 3 VEGF receptors [59]. A phase I study using cedi-
ranib in prostate cancer showed dose-limiting toxicity occur-
ring at 30mg dose, with a dose of 20mg/day being the MTD
[60].AphaseIIstudyindocetaxel-resistantmetastaticCRPC
showed encouraging results, with 13 of 23 evaluable patients
havingdecreasesinsofttissuelesions,4ofwhommetcriteria
forpartialresponse[61].Shrinkageofmetastaticvisceraldis-
ease to the lymph nodes, lung, liver, and bone was observed
although the PSA levels have not corresponded with imaging
responses. Similar to sorafenib, posttreatment PSA declines
were noted in patients following drug discontinuation, in the
absence of administration of a new drug treatment.
4. Mechanismsof Resistance
It was initially believed that angiogenesis inhibition carries
little potential risk for resistance [62]. However, recent stud-
ies suggest that this may not be the case. For instance, exper-
iments using mouse endothelial cells isolated from human
tumor xenografts when compared to normal endothelial
cell counterparts showed acquired cytogenetic abnormalities
[63]. Furthermore, regrowth of tumors during treatment
with antibodies to VEGFR1 and R2 after an initial period
of growth suppression was seen in a pancreatic islet cell
tumor murine model, suggesting development of pheno-
typic resistance to VEGFR2 blockade [64]. This resistance
to VEGF blockade involves various possible mechanisms,
including an adaptive evasion or intrinsic nonresponsiveness
of tumors [10, 65]. Adaptive evasion suggests upregulation
of alternative signaling pathways to circumvent the blocked
angiogenic pathway, recruitment of bone-marrow derived
proangiogenic cells, or increased surrounding pericyte cov-
erage. Intrinsic nonresponsiveness, on the other hand,
suggests innate indiﬀerence of the tumor to antiangiogenic
therapy, which supports the clinical observation that not
all patients respond to antiangiogenic therapy. These obser-
vations certainly have clinical implications since strategies
to obviate these acquired or inherent resistances must be
sought. Strategies that include combination or sequential
approach of antiangiogenic therapies may be one approach
to address this. In addition, genetic variability in the VEGF
promoter can be used as a potential predictive biomarker for
bevacizumab activity.
5. FutureDirections
Angiogenesis inhibitors have the potential to enhance ther-
apeutic options for patients with prostate cancer. Various
combinations, not limited to chemotherapy, have been used
with promising results. For instance, interesting results
have been seen using a combination of bevacizumab with
the autologous dendritic cell-based vaccine sipuleucel-T
(Provenge; Dendreon, Seattle, WA) in patients with bio-
chemical recurrence [66]. This vaccine has demonstrated
improved overall survival relative to placebo in a phase III
trialinmetastaticCRPC[67]andmay warrantfurtherinves-
tigation with bevacizumab. With the success seen in various
other tumor types using antiangiogenesis, similar results are
likely seen in prostate cancer. However, several challenges
remain, including the use of appropriate assessment tools
for measuring response in metastatic prostate cancer and
the use of candidate surrogate biomarkers for correlating
response. Perhaps the use of pharmacogenetics may help
in identifying patients who may beneﬁt or develop undue
toxicity from the use of antiangiogenic agents. For instance,
inatrialusingbevacizumabinbreastcancerpatients,varying
single nucleotide polymorphisms (SNPs) in the regulatory
regions of the VEGF gene may predict for improved median
overall survival or protection from hypertension, which is
one of the most commonly encountered toxicity with the use
of bevacizumab [68]. The beneﬁt of angiogenesis inhibitors
has become a reality in several tumor types, with signiﬁcant
potential in prostate cancer.
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